Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gembloux – page 103

1 845 clinical trials in Gembloux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gembloux at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Gembloux

Open in trial search

Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Universitair Ziekenhuis Gent

Study of BMS-986446 for Early Alzheimer's Disease Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:QEL-001
  • Sponsor:Quell Therapeutics Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.